A fourth challenger from DualityBio and BioNTech
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
Biohaven aims to become an oncology fast follower
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
Next for Trodelvy: small-cell lung cancer
Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.
Triple meeting 2024 – Zai Lab impresses in small cell
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
European radiopharmaceuticals head for the clinic
First-in-human study starts include radioligands from Akiram and Philogen.
